



Regionshospitalet Viborg, Skive
Hjertemedicinsk afdeling
Heibergs Allé 4
8800 Viborg

Pfizer Danmark

Aarhus Universitet
Institut for Klinisk Medicin
Palle Juul-Jensens Boulevard 99
8200 Aarhus N

07 November 2016

Agreement on support to project: Real-life data on use of NOACs and Warfarin in relation to cardioversion for atrial fibrillation.

By request of Overlæge, PhD Dorthe Svenstrup Møller, Hjertemedicinsk afdeling, Pfizer is very pleased to confirm that it will provide support to the above-mentioned research project in the form of 240.000 DKK.

The support will be given to Hjertemedicinsk afdeling and is approved by Ledende overlæge, Ph.D. Jens Refsgaard, Hjertemedicinsk Afdeling on behalf of Regionshospitalet Viborg, Skive.

Furthermore the support is approved by Hospitalsdirektør Lars Dahl Pedersen who is responsible for the hospital account to which the funding is paid to. The payment will be transferred to Jyske Bank, Sct. Mathias Gade, 8800 Viborg. Account owner: Hospitalsenhed Midt, Regionshospitalet Viborg, Heibergs Allé 6, 8800 Viborg. Account no: Reg. Nr. 7831 konto 1441022, Reference "Projekt 121921, AGR-2016-8778".

The research project will be executed by Hjertemedicinsk afdeling through its employee Dorthe Svenstrup Møller.

The purpose of the research project is to get information on patient pathways and safety in relation to cardioversion in a contemporary structured hospital base AF-service can be useful for patients, clinicians, hospital administrator and policy makers and Pfizer wishes to support this purpose.

Hjertemedicinsk afdeling will ensure that the support is used solely for professional and scientific purposes in relation to the research project and undertakes that any surplus from the support not used in accordance herewith will be refunded.

Upon request from Pfizer the Hospital must document that the support is spend in accordance with the above-mentioned.

Hjertemedicinsk afdeling undertakes the full responsibility for the execution of the research project and Pfizer disclaims every right to interfere with the execution and any other part of the research project.

Furthermore Hjertemedicinsk afdeling will be responsible for compliance with all applicable law.

Pfizer shall not be liable for damages of any kind and Pfizer provides no indemnification of any type.

We kindly ask you to return the signed agreement to Pfizer ApS.

Please complete and sign the attached Payment Form and return to Pfizer ApS as soon as possible together with the signed agreement. Please note that Pfizer will be precluded from providing you with the financial support if you do not state a CVR-number on the Payment Form.

This agreement will be available on Pfizer's webpage (www.pfizer.dk) when the support is granted and for a period of 2 years thereafter.

Information regarding name and contact information in relation to this agreement will be stored in a Pfizer global electronic system. You should be aware that some of the members of Pfizer group, legal counsel and/or regulatory authorities could have access to information as described above are located in countries whose laws protecting personal information may not be equivalent to those in your country. In particular, personal data disclosed to Pfizer Inc. by members of the Pfizer group within the European Economic Area and Switzerland is protected by Pfizer Inc.'s participation in the "safe harbour" schemes administered by the U.S. Department of Commerce.

You have right to access or, where incorrect, amend information pertaining to you that is in Pfizer's possession.

The support is provided under the provisions set forth in this agreement and in accordance with Pfizer's anti-corruption provisions (Appendix A).

By signing this page, the Requester confirms that the Requester has read and understood Pfizer's policy relating to bribery and corruption pursuant to appendix A and that the support is spend in accordance with the above mentioned terms and conditions.

Date:

17/11-2016


Signature of authorized signatory on behalf of PI ApS:



Troels Reiche
Medical Director

Date:

Signature of authorized signatory on behalf of Regionshospitalet Viborg, Skive:

 8/11-2016

Dorte Svenstrup Møller
Overlæge, PhD
Hospitalsenhed Midt

Accepted by:

 8/11-2016

Jens Refsgaard
Ledende overlæge, Ph.D.
Hjertemedicinsk Afdeling, Hospitalsenhed Midt

 8/11-16

Lars Dahl Pedersen
Hospitalsdirektør
Hospitalsenhed Midt

 14/11-16

Ulrich Fredberg
Ledende overlæge, Ph.D., Associate Professor
Diagnostisk Center, Hospitalsenhed Midt

 16/11-16

Kristjar Skajaa
Head of Department of Clinical Medicine Aarhus
University

Appendix A – Standard Anti-Corruption Provisions

- 1.1 The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;
- 1.2 Neither your entity and, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, have not accepted, and will not accept in the future, such a payment; and
- 1.3 Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support, has used or intend[s] to use any portion of the support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.
- 1.4 Pfizer may at any time publicly disclose that it has provided you with financial support, including the amount of such support.